MOUNTAIN VIEW, Calif., May 10 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, expanded its management team today by hiring Jean-Francois Marier, Ph.D., to fill the newly-created position of Vice President, Reporting and Analysis Services. Dr. Marier will lead the new client offering and report to Mark Hovde, Pharsight SVP.
"Together with our software and Strategic Consulting Services, this expansion of our services allows us to address the full spectrum of client needs in modeling and simulation. We will now be able to meet growing customer demand for reporting and analysis of pharmacokinetic/pharmacodynamic (PK/PD) data generated in clinical and preclinical studies supporting new drug approvals," said Mr. Hovde. "These studies include toxicokinetic, single- and multiple-ascending dose, drug-drug interaction, renal and hepatically impaired, fed-fasted, bioequivalence/bioavailability, QT prolongation, and others. Based upon our strong existing relationships with our clients, our software, and industry-leading modeling and simulation domain expertise, we believe we now offer a more efficient and comprehensive set of services to our clients.
"One key advantage will be our ability to leverage Pharsight's state-of- the-art software tools for high productivity, compliant analysis, data management, and report production," continued Mr. Hovde. "In this way, we believe we now offer the most well-rounded suite of products and services focused on modeling and simulation. We believe our new services will complement our existing software and Strategic Consulting Services offerings and have the potential to grow into a major revenue contributor."
Dr. Marier brings to Pharsight a decade of experience and a successful track record of leadership in the delivery of PK/PD reporting and analysis projects supporting new drug approval. "Throughout his career, Jean-Francois has proven his ability to lead teams assisting pharmaceutical and biotech clients with their PK/PD reporting and analysis needs," continued Mr. Hovde. "We believe Jean-Francois will help Pharsight drive our growth in this attractive market. We welcome Jean-Francois to Pharsight and look forward to his many contributions."
Jean-Francois Marier, Ph.D.
Dr. Marier has extensive expertise in the various phases of drug development, and has directed analysis and provided drug development consultation in all types of studies involving PK/PD data, including bioequivalence/bioavailability studies, studies in special populations, QT prolongation studies, and others. Before joining Pharsight, Dr. Marier held the position of Director, PK/PD Department, with MDS Pharma Services, Inc., in Montreal. During his career at MDS Pharma Services, Dr. Marier has been involved in hundreds of studies in early clinical research.
Dr. Marier graduated from the University of Montreal, Faculty of Pharmacy with a doctoral degree in Pharmaceutical Sciences, with emphasis on new methods in population PK and PD analyses. He also holds an M.S. in Pharmacology at the Faculty of Medicine and a B.S. in Chemistry. He is primary or co-author of more than 20 peer-reviewed manuscripts in the field of pharmacokinetics and dozens of scientific abstracts and poster presentations. He is a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), the American Association of Pharmaceutical Scientist (AAPS), and American College of Clinical Pharmacology (ACCP).
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Safe Harbor
This press release includes forward-looking statements, including statements regarding our growth opportunities and market position and the demand and market for our products and services. These forward-looking statements involve risks and uncertainties, and factors that could cause actual results to differ materially include the following: changes in the demand for Pharsight's products and services, uncertainties involved in pharmaceutical drug development, changes in government regulation of the pharmaceutical industry, changes in Pharsight's research and development focus or operating strategies and the failure to develop new products and services or to keep pace with technological changes. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 12, 2007 All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Trademarks and Registered Trademarks
Pharsight is a registered trademark of Pharsight Corporation.
Pharsight CorporationCONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or Media,Jennifer Saunders, +1-646-201-5431, both of EVC Group
Web site: http://www.pharsight.com//
